Type 2 diabetes and testosterone deficiency audit launched
Healthcare professionals are being asked to take part in a global audit looking at testosterone deficiency audit in men with type 2 diabetes.
Launched by the ABCD, it had been postponed by COVID-19, but has now been launched as pressure eases on the NHS.
The condition has a high prevalence with 40 per cent of men with type 2 diabetes believed to have symptomatic testosterone deficiency.
In addition, testosterone deficiency is associated with an adverse effect on cardiovascular risk factors, osteoporosis, reduced muscular strength (including frailty), anaemia and reduced psychological well-being.
It is also associated with an increased mortality in type 2 diabetes and independently in cardiovascular disease.
Testosterone replacement has been shown to improve many health ailments including sexual dysfunction, insulin resistance and can also reduce cholesterol and body weight.
In previous ABCD audits, findings have suggested that people who are treated with medications in the real world tend to be different from those in clinical trials.
That is why this audit is being set up to “establish the extent to which the patients treated, and the impact of testosterone treatment on them, matches the findings in the clinical trials”.
For more information and to sign up to take part, click here.